Partnerships & Collaborations
Better Together
Together we share one goal: to accelerate the development and manufacture of safe advanced therapies.
Together we cure®.
We all know that some serious innovation is needed to get cell and gene therapies to the patients who need them. This Innovation cannot happen without collaboration. The problems our industry faces are too complex and the stakes are too high for us to work alone.
For more than a decade, Akron Bio has worked closely with academic and industry partners to establish standards, reduce the cost of goods, and develop safer, commercial-ready materials.
We’re better when we work together. That's why we believe in building strong and lasting partnerships.
Here are some of our ongoing collaborations. Get in touch with us if you have big ideas to advance the cell and gene therapy industry through manufacturing innovation.
Octapharma
In January of 2021, Akron signed an exclusive global agreement to manufacture virus-inactivated Human AB Serum for the cell and gene therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma. Leveraging pharmaceutically licensed, virus inactivated pooled plasma as a starting material, this product offers greater batch-to-batch consistency and an excellent safety profile. Learn more about our exclusive partnership with Octapharma.
Multiply Labs
In December of 2024, Akron announced a partnership with Multiply Labs to automate the use of cGMP-compliant liquid cytokines in cell therapy manufacturing. This collaboration aims to enhance efficiency and scalability by integrating Akron Bio’s high-quality cytokines with Multiply Labs’ robotic systems, streamlining production for advanced therapies.
Charles River Laboratories
Charles River Laboratories and Akron Bio have joined forces to enhance cell therapy manufacturing by integrating Akron’s cGMP-compliant materials into Charles River’s cell therapy platform. This collaboration aims to improve efficiency, scalability, and regulatory compliance, accelerating the development of advanced therapies.
Terumo Blood and Cell Technologies
In January 2025, Terumo Blood and Cell Technologies and Akron Bio have successfully completed a collaborative study on Mesenchymal Stem Cell (MSC) expansion using the Quantum Flex bioreactor. The study demonstrates the effectiveness of Akron Bio’s cGMP virus inactivated fibronectin in scaling MSC production, supporting a seamless transition from research to clinical manufacturing.
Akron Bio and Terumo Blood and Cell Technologies
Custom Services
Custom size and configuration vials, syringes, bags and more. We manufacture custom recombinant proteins, media and buffers for cell and gene therapy products based on your specifications, all under cGMP guidelines.
Capitalizing on our established platform for manufacturing cGMP-compliant clinical and commercial grade ancillary products. Our broad expertise and vision are highly sought after, particularly for challenging projects which demand carefully considered approaches.
